Last reviewed · How we verify
DKF-MA102
DKF-MA102 is a small molecule drug that targets the molecular target.
DKF-MA102 is a small molecule drug that targets the molecular target. Used for Hypertension.
At a glance
| Generic name | DKF-MA102 |
|---|---|
| Also known as | Leuprorelin acetate |
| Sponsor | Dongkook Pharmaceutical Co., Ltd. |
| Target | molecular target |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
DKF-MA102 works by binding to the molecular target, which results in the desired therapeutic effect.
Approved indications
- Hypertension
Common side effects
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DKF-MA102 CI brief — competitive landscape report
- DKF-MA102 updates RSS · CI watch RSS
- Dongkook Pharmaceutical Co., Ltd. portfolio CI